trial

EMD 128130 for the Treatment of Parkinson's Disease

NCTId NCT00009048
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 30
Sponsored by National Institute of Neurological Disorders and Stroke (NINDS)
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
30
Study type
Interventional
Allocation
—
Model
—
Masking
—
Start
2001-01
Primary completion
—
Eligibility
ALL

Interventions & indications

Drugs
EMD 128130IV Levodopa

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS)Lead Sponsor

Sites

1 total
Bethesda, United States

Facts & assertions

3 sourced
Enrollment
30
Phase
PHASE2
Status
COMPLETED
relationships
The graph out of here
drug
EMD 128130
drug
IV Levodopa
drug
lead_sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
company
indication
Psychotic Disorders
indication
Parkinson's Disease
indication
Parkinson Disease
indication